Zoladex in the treatment of premenopausal metastatic breast cancer patients.
In an open phase II, multicentre study with 118 pre- or perimenopausal women with histologically proven advanced breast cancer, Zoladex depot (3.6 mg) has been shown to produce an effective castration and response rates, which are comparable to those from oophorectomy.
Kaufmann
M
M
Universitats-Frauenklinik, Heidelberg, FRG.
D000008:Abdominal Neoplasms / Q000556:secondary; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005260:Female; D017273:Goserelin; D006801:Humans; D015337:Multicenter Studies as Topic
D003692:Delayed-Action Preparations; D017273:Goserelin; D002064:Buserelin